REGENXBIO Inc. (RGNX)
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Address
9804 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
Founded
2008
Number of Employees
344
Website
http://www.regenxbio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)